Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. For The Oral Interlukin-23 Receptor Antagonist Drug Candidate For The Treatment of Inflammatory Bowel Disease

Long-standing relationship between Johnson& Johnson Innovation, Janssen and Protagonist Therapeutics leads to advancement of promising oral drug candidate for Crohn ’s disease and ulcerative colitis
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news